I personally believe that in the current environment with M&A heating up (3 biotech stocks taken out already on the ASX), if NEU with the data they and the market have been so excited about can't do a deal or a straight sell out and wants to raise money to go Phase 3 alone which is very risky given its CNS and autism, it will not reflect strongly on the company and the data they have generated so far... I think with the US tax changes companies are flushed with cash and this is the time for NEU management to get the best deal. We are talking about 100% premiums or more in take out values as seen with RSH and VLA.
My preference will be do a deal or sell the company outright.
Add to My Watchlist
What is My Watchlist?
